Neuroferritinopathy: missense mutation in FTL causing early-onset bilateral pallidal involvement by Maciel, P. et al.
CME Neuroferritinopathy:
Missense mutation in
FTL causing early-
onset bilateral pallidal
involvement
Abstract—The authors identified a missense mutation in the FTL gene
(474GA; A96T) in a 19-year-old man with parkinsonism, ataxia, corticospinal
signs, mild nonprogressive cognitive deficit, and episodic psychosis. This muta-
tion was also present in his asymptomatic mother and younger brother, who
had abnormally low levels of ferritin in the serum. The patient and his mother
displayed bilateral involvement of the pallidum.
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Neuroferritinopathy, an autosomal dominant disease
caused by mutations in the ferritin light polypeptide
gene (FTL),1 has been reported as a movement disor-
der with heterogeneous presentations starting in the
fourth to sixth decades, with either predominating
chorea, dystonia, or a bradykinetic-rigid syndrome
(table). The cases of neuroferritinopathy previously
described1-5 were associated with the insertion of an
adenine in position 460–461 of the FTL gene, or a
CT dinucleotide in position 498–499, both of which
caused frameshifts, originating FTL polypeptides in
which the C-terminal amino acid residues were
changed and the length of the protein was extended.
We describe a novel missense mutation in the FTL
gene, associated with an earlier onset of disease.
Methods. A 19-year-old man of gypsy ancestry with mild non-
progressive mental retardation (IQ  60), showed no evidence of
anoxia at birth and developed gait disturbances by age 13. He was
admitted at the ages of 14 and 18 to different institutions, with
episodes of acute psychosis responsive to neuroleptics. In the lat-
est admission he was diagnosed with Wilson disease and received
treatment with d-penicillamine, valproic acid, and trazodone.
Eleven months later, he was admitted to our hospital in a state of
confusion with apathy. Neurologic examination showed severe
ataxia, bradykinetic-rigid syndrome, and plantar extensor re-
sponses. Laboratory findings included normal liver function,
plasma ceruloplasmin of 26 ng/mL, copper of 76 ng/mL, and urine
copper of 8.1 ng/mL. Kayser–Fleischer rings were not present.
Abdominal ultrasound was normal. Serum ferritin was 16 ng/mL
(N  20 to 300), serum iron was 174 g/mL (N  65 to 175,) and
IBC was 376 g/mL (N  250 to 450). MRI showed slightly asym-
metric pallidal hyperintensity in T2 and fluid-attenuated inver-
sion recovery images and hypointensity in T1. A diffuse atrophy
was also evident, predominating in the frontoparietal and ver-
mian regions (figure 1). Upon withdrawal of all medication the
patient experienced a dramatic improvement, resuming his daily
routine. After 1 year, neurologic examination revealed mild brady-
kinesia, symmetric cog-wheel rigidity, slight ataxia, and bilateral
Babinski sign. No behavioral or cognitive deterioration were ob-
served during this follow-up period.
We observed nine family members (figure 2a) and performed
biochemical and genetic studies in all and MRI studies in the
patient, his mother, and younger brother.
None of the other relatives observed had signs of neurologic or
psychiatric disease, other than an uncle who had been previously
diagnosed with schizophrenia. The patient and his mother dis-
played a similar pattern of pallidal necrosis in MRI (see figure 1).
We extracted DNA from 50 randomly selected and anonymous
Guthrie cards obtained from the national neonatal phenylketonu-
ria screening program. This study was authorized by the ethics
committee of the Medical Genetics Institute where samples were
obtained.
After informed consent was obtained, genomic DNA was ex-
tracted from blood samples using the Puregene system (Gentra
Systems, Minneapolis, MN) according to the manufacturer’s proto-
col and from Guthrie cards using Chelex. For analysis of the FTL
gene (OMIM 134790), DNA was amplified by PCR and sequenced,
using primers FTLgIF, FTL1bF, FTL2R, FTL3F, FTL4R1 and
primers FTLp1 (5=TGAGCCACTTCTTCCGCGAAT3=) and FTLp2
(5=TGAGCCACTTCTTCCGCGAAC3=). For confirmation of the
G474A mutation, a PCR-RFLP assay was developed, using prim-
ers FTL3F/FTL4R for PCR amplification, followed by digestion
with BsaHI.
Serum ferritin levels were evaluated using chemiluminescence
immunoassay, serum iron by colorimetric analysis without precip-
itation, and serum transferrin by nephelometry.
Results. Upon sequencing the coding region of the FTL
gene, we identified the presence in the proband of a G to A
mutation at position 474 of the cDNA (NM_000146), that
results in the codon GCC being changed to ACC, thus
originating an amino acid substitution in which alanine 96
is replaced by threonine (figure 2b). The same mutation
was detected in the 40-year-old mother, who is asymptom-
atic but displays similar MRI findings, and in her 13-year-
old unaffected son. The A96T mutation was not present in
the control population and in all other family members
tested (figure 2c), including the maternal grandmother,
suggesting inheritance from the maternal grandfather’s
side. This family member had died of accident at the age of
45, and it was impossible to test that branch of the family,
so we could not confirm this hypothesis.
The serum ferritin levels of the patient were abnor-
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mally low (16 ng/mL); his mother and his younger brother
also had low plasma ferritin (mother: 13 ng/mL; younger
brother: 10 ng/mL), in the presence of normal values of other
iron parameters. All other relatives studied had levels of fer-
ritin in plasma within normal limits (see figure 2a).
Multiple sequence alignment revealed that the alanine
residue at position 96 of the FTL polypeptide was con-
served among distantly related species (figure E-1 on the
Neurology Web site at www.neurology.org). Theoretical
modeling of the effect of the A96T mutation upon the
structure of the FTL polypeptide shows that this residue is
located in the same region, concerning tertiary structure,
that is affected by the 460–461InsA mutation.
Discussion. Evidence to suggest that the alanine
to threonine substitution at position 96 of the FTL
polypeptide is the cause of disease in this patient
comes from evolutionary data showing conservation
of this amino acid and from structural modeling of
the polypeptide that predicts an important effect in a
functionally relevant region (appendices E-1 and
E-2). Additional evidence comes from the associa-
tion of this mutation with low serum ferritin levels
in all individuals tested, and from the consistency
of MRI findings in the patient and his mutation
carrier mother, suggesting expression of the muta-
tion in specific structures of the CNS, namely the
globus pallidus (figure 1). Whereas the patient,
once removed from all medication, had a mild clin-
ical presentation, the mother remains asymptomatic,
in spite of MRI findings. This difference in age at onset
is not unexpected in diseases related to iron accumula-
tion, in which women, given the iron loss associated
with menses, are generally less affected.
One particular feature of the neuroferritinopathy
cases described in the literature,1-3 (which we have
also observed in all the A96T mutation carriers), are
the lower than normal plasma ferritin levels, in spite
of evidence of iron and ferritin accumulation in the
CNS; this may reflect an altered regulation of its
secretion process6 or instability and increased turn-
over of mutant ferritins. Why mutations in FTL lead
to a deregulation of iron storage in the CNS remains
unclear, but evidently there are very specific target
regions, displaying selective vulnerability either to
iron accumulation or to the effect of accumulated
iron and ferritin. MRI of the brain showed consider-
able hyperintensity on T2-weighted images in the
pallidum, which is consistent with other reports of
neuroferritinopathy. Yet, in contrast with previous
descriptions, no significant involvement of the puta-
men, thalamus, substantia nigra and dentate nuclei
was found in the patient. As in Wills’ report,2 we also
Table Clinical, imaging and neuropathology findings in families with autosomal dominant neuroferritinopathy
Family origin Cumbria, North West, England1 France3 France5
No. of patients/ family
members with mutation
2/5 7/7 6/7*
Age at onset, y 40–55 (1 on 3rd decade) 24–58
(2 on 3rd decade)
20
Mode of onset Choreoathetosis  dystonia Dystonia Tremor
Disease duration, y   38
Cognitive impairment Frontal lobe impairment (1)† Frontal syndrome (2);
dementia (1)
Frontal syndrome; dementia
Parkinsonism   
Dystonia ; blepharospasm 1† with palatal
tremor, buccolingual dyskinesia and
generalized dystonia
; blepharospasm ; buccolingual dyskinesia, hand
and feet dystonia
Choreoatetosis   
Pyramidal signs   
Cerebellar signs   
Neuropathy   
Ferritin serum levels 4–16 g/L (5 with mutation)  
Imagery BG cavitations BG cystic changes (3) Severe cerebellar atrophy;
BG T2 hypo, T1 hyperintensities
Neuropathology Reddish discoloration of the BG;
iron positive deposits in GP; spherical
inclusions positive for ferritin
 Greyish discoloration of C and P;
small cavities in P;
intranuclear bodies in neurons and glia
positive for ferritin
Mutation FTL 460–461InsA FTL 460–461InsA FTL 498–499InsTC
* Only one patient described.
† Reference 2.
AD  autosomal dominant; BG  basal ganglia; GP  globus pallidus; C  caudate; P  putamen;   present;   most impres-
sive feature;   absent.
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failed to find evidence of altered mineralization of
the pallidum. In accordance to that report, a signifi-
cant brain atrophy was detected in the patient, but
not in his mother.
At the clinical level, we cannot affirm that the
patient’s psychotic episodes are in definite associa-
tion with the A96T mutation, since a non-carrying
uncle had schizophrenia. This particular FTL muta-
tion does appear to be associated, in this family, with
pallidal lesions, in two of the carriers, and, in one,
with an early onset slowly progressive form of the
disease, leading to minor functional impairment
after six years. The identification of two pre-
symptomatic individuals of 13 and 40 years provides
an excellent opportunity for studying the onset of
clinical expression and the disease process in neuro-
ferritinopathy.
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Figure 1. MRI study of the patient (a through e) and his
mother (f). A bilateral pallidal hyperintensity can be ob-
served in axial T2-weighted (a), fluid-attenuated inversion
recovery (b), and coronal T2 images; no significant sur-
rounding hypointensities were noted in these images. A
diffuse atrophy of the parenchyma could also be appreci-
ated, including the vermian region (d). Similar T2-
weighted images of the patient (e) and his mother (f)
revealed the same pattern of pallidal involvement, al-
though the extent of signal alterations was smaller in the
mother’s study, where no concomitant parenchimal atro-
phy was noted.
Figure 2. Pedigree of the family in study (a): black
square  individual with clinical signs, low ferritin levels,
MRI findings and FTL mutation; half-filled circle  low
ferritin levels, MRI findings and FTL mutation; low fer-
ritin levels and FTL mutation; circle or square with an
n  no FTL mutation. Molecular analysis revealing the
heterozygous 474 AG sequence change in the FTL gene:
(b) sequencing chromatogram of the PCR product includ-
ing exons 3 and 4 of the patients and (c) PCR-RFLP anal-
ysis of all family members available for study. C- control
individual, CU –undigested PCR product, B-PCR blank.
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